Norges Bank
KZR

Norges Bank’s Kezar Life Sciences KZR Stock Holding History

Norges Bank’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-49,150
Closed -$8.17M – 2116
2022
Q1 		$8.17M Hold
49,150
– – ﹤0.01% 1766
2021
Q4 		$8.22M Buy
+49,150
New +$5.55M ﹤0.01% 1814
2018
Q3 		– Sell
-500
Closed -$86K – 2146
2018
Q2 		$86K Buy
+500
New +$87.2K ﹤0.01% 2118

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Norges Bank's KZR Position: Q2 2022 in Review

Norges Bank sold out of Kezar Life Sciences (KZR) in Q2 2022, closing a stake of 49,150 shares — an estimated $8.17M sold.

Norges Bank first reported a position in KZR in Q2 2018 and held it in 3 quarters. The position peaked at $8.22M in Q4 2021. 127 funds tracked by Wall St. Rank hold KZR as of Q2 2022.

  • Norges Bank reported no remaining Kezar Life Sciences position as of Q2 2022 after selling out during the quarter.
  • Norges Bank sold 49,150 Kezar Life Sciences shares in Q2 2022, an estimated $8.17M.
  • Norges Bank first reported a position in Kezar Life Sciences in Q2 2018 and held it in 3 quarters.
  • Norges Bank's Kezar Life Sciences position peaked at $8.22M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.